Xeris Biopharma Holdings, Inc.XERSEarnings & Financial Report
Xeris Biopharma Holdings, Inc. is a specialty biopharmaceutical company that develops and commercializes targeted therapies for rare endocrine, metabolic, and dermatological conditions. It operates across global markets, focusing on delivering accessible, easy-to-administer treatment options for underserved patient segments.
XERS Q4 FY2025 Key Financial Metrics
Revenue
$85.8M
Gross Profit
N/A
Operating Profit
$16.8M
Net Profit
$11.1M
Gross Margin
N/A
Operating Margin
19.5%
Net Margin
12.9%
YoY Growth
42.8%
EPS
$0.07
Xeris Biopharma Holdings, Inc. Q4 FY2025 Financial Summary
Xeris Biopharma Holdings, Inc. reported revenue of $85.8M (up 42.8% YoY) for Q4 FY2025, with a net profit of $11.1M (up 316.7% YoY) (12.9% margin).
Key Financial Metrics
| Total Revenue | $85.8M |
|---|---|
| Net Profit | $11.1M |
| Gross Margin | N/A |
| Operating Margin | 19.5% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Xeris Biopharma Holdings, Inc. Q4 FY2025 revenue of $85.8M breaks down across 2 segments, led by Products at $83.4M (97.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $83.4M | 97.2% |
| Other | $2.4M | 2.8% |
Xeris Biopharma Holdings, Inc. Annual Revenue by Year
Xeris Biopharma Holdings, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $291.8M).
Xeris Biopharma Holdings, Inc. Quarterly Revenue & Net Profit History
Xeris Biopharma Holdings, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $85.8M | +42.8% | $11.1M | 12.9% |
| Q3 FY2025 | $74.4M | +37.1% | $621.0K | 0.8% |
| Q2 FY2025 | $71.5M | +48.8% | $-1.9M | -2.7% |
| Q1 FY2025 | $60.1M | +47.9% | $-9.2M | -15.3% |
| Q4 FY2024 | $60.1M | +35.4% | $-5.1M | -8.5% |
| Q3 FY2024 | $54.3M | +12.3% | $-15.7M | -29.0% |
| Q2 FY2024 | $48.1M | +26.5% | $-15.0M | -31.2% |
| Q1 FY2024 | $40.6M | +22.4% | $-19.0M | -46.7% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $40.6M | $48.1M | $54.3M | $60.1M | $60.1M | $71.5M | $74.4M | $85.8M |
| YoY Growth | 22.4% | 26.5% | 12.3% | 35.4% | 47.9% | 48.8% | 37.1% | 42.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $336.6M | $331.7M | $321.1M | $323.1M | $315.5M | $334.7M | $370.2M | $383.5M |
| Liabilities | $345.8M | $351.0M | $349.4M | $352.7M | $350.6M | $354.0M | $371.1M | $369.8M |
| Equity | $-9.2M | $-19.3M | $-28.3M | $-29.6M | $-35.1M | $-19.3M | $-861000 | $13.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-20.3M | $-10.3M | $-8.3M | $2.0M | $-10.0M | $182000 | $18.4M | $20.0M |